3:25-cv-19039
AbbVie Inc v. DR Reddy's Laboratories Ltd
I. Executive Summary and Procedural Information
- Parties & Counsel:
- Plaintiff: AbbVie Inc. (Delaware) and Allergan Pharmaceuticals International Limited (Ireland)
- Defendant: Dr. Reddy's Laboratories, Ltd. (India) and Dr. Reddy's Laboratories, Inc. (New Jersey)
- Plaintiff’s Counsel: McCARTER & ENGLISH, LLP
- Case Identification: 3:25-cv-19039, D.N.J., 12/29/2025
- Venue Allegations: Venue is based on Defendant Dr. Reddy's Laboratories, Inc. having its principal place of business in New Jersey, making it a resident of the district.
- Core Dispute: Plaintiffs allege that Defendants' submission of an Abbreviated New Drug Application (ANDA) to market generic versions of QULIPTA® (atogepant) tablets infringes four patents related to methods of treating migraine.
- Technical Context: The technology involves the use of atogepant, an oral calcitonin gene-related peptide (CGRP) receptor antagonist, for the preventive treatment of migraine.
- Key Procedural History: This action was initiated under the Hatch-Waxman Act following Plaintiffs' receipt of a notice letter from Defendants regarding their ANDA filing, which included a Paragraph IV certification alleging the patents-in-suit are invalid, unenforceable, or will not be infringed. The complaint notes that the patents-in-suit are also the subject of separate litigation against other generic manufacturers.
Case Timeline
| Date | Event |
|---|---|
| 2018-06-08 | U.S. Patent No. 12,383,545 Priority Date |
| 2020-07-29 | U.S. Patent No. 12,090,148 Priority Date |
| 2021-09-27 | U.S. Patent Nos. 12,350,259 & 12,465,598 Priority Date |
| 2021-09-28 | FDA Approval of QULIPTA® New Drug Application |
| 2024-09-17 | U.S. Patent No. 12,090,148 Issue Date |
| 2025-07-08 | U.S. Patent No. 12,350,259 Issue Date |
| 2025-08-12 | U.S. Patent No. 12,383,545 Issue Date |
| 2025-11-11 | U.S. Patent No. 12,465,598 Issue Date |
| 2025-11-17 | Plaintiffs Received Defendants’ Notice Letter |
| 2025-12-29 | Complaint Filing Date |
II. Technology and Patent(s)-in-Suit Analysis
U.S. Patent No. 12,090,148 - Treatment of Migraine
The Invention Explained
- Problem Addressed: The patent background describes a need for optimized and targeted oral treatments for the prophylactic (preventive) treatment of migraine, noting that existing oral preventives are not specifically designed for migraine and CGRP-targeted treatments are limited to injectables (’148 Patent, col. 1:35-48).
- The Patented Solution: The invention provides a method for the preventive treatment of migraine by orally administering a specific daily dose of atogepant (10 mg, 30 mg, or 60 mg). This administration is disclosed to result in a statistically significant reduction in the number of monthly migraine days and may also be associated with a reduction in body weight (’148 Patent, Abstract; col. 2:3-17).
- Technical Importance: The invention provided a method for using a small-molecule oral medication to target the CGRP pathway for migraine prevention, offering a different mode of administration compared to injectable monoclonal antibodies targeting the same pathway (’148 Patent, col. 1:39-43).
Key Claims at a Glance
- The complaint does not identify specific asserted claims. Claim 1 is the first independent claim.
- Key elements of independent claim 1 include:
- A method for the preventive treatment of migraine in a patient having migraine headaches.
- Administering to the patient 60 mg atogepant, or a pharmaceutically acceptable salt thereof, once daily for more than 12 weeks.
- Wherein the administration is associated with a reduction in mean monthly migraine days.
- Wherein the administration is associated with a reduction from baseline in body weight.
U.S. Patent No. 12,350,259 - Methods of Treating of Migraine
The Invention Explained
- Problem Addressed: The patent addresses the need for safe and effective dosing of oral CGRP treatments, particularly when a patient is taking other medications that could cause adverse drug-drug interactions (’259 Patent, col. 1:41-45).
- The Patented Solution: The invention provides a specific dosing method for atogepant in patients who are also taking a strong CYP3A4 inhibitor, a class of drugs that affects atogepant's metabolism. The patented solution is to administer a reduced dose of 10 mg of atogepant once daily to prevent potentially harmful increases in atogepant exposure while maintaining effective migraine prevention (’259 Patent, Abstract; col. 3:15-29).
- Technical Importance: This method provides a defined protocol to safely manage drug-drug interactions, allowing patients to continue preventive migraine treatment with atogepant while also taking other necessary medications that use the same metabolic pathway (’259 Patent, col. 4:15-29).
Key Claims at a Glance
- The complaint does not identify specific asserted claims. Claim 1 is the first independent claim.
- Key elements of independent claim 1 include:
- A method for the preventive treatment of migraine in a patient undergoing concurrent treatment with a strong CYP3A4 inhibitor.
- The method comprises orally administering 10 mg atogepant once daily to the patient.
- Wherein the patient’s migraines are safely and effectively treated.
U.S. Patent No. 12,383,545 - Treatment of Migraine
Technology Synopsis
The patent addresses the need for oral CGRP-based migraine preventives that are both effective and have a favorable side-effect profile (’545 Patent, col. 1:43-48). The claimed invention is a method of treating migraine by administering specific daily doses of atogepant (10 mg, 30 mg, or 60 mg) that does not significantly affect the patient's level of liver enzymes (’545 Patent, Abstract; col. 6:40-45).
Asserted Claims
The complaint does not specify asserted claims; independent claims 1, 7, and 13 are representative.
Accused Features
The accused features are Defendants' filing of an ANDA for 10 mg, 30 mg, and 60 mg generic atogepant tablets, which, upon approval, would be prescribed for the preventive treatment of migraine in a manner that allegedly practices the claimed methods (Compl. ¶¶1, 128).
U.S. Patent No. 12,465,598 - Methods of Treating Migraine
Technology Synopsis
This patent addresses the safe and effective use of atogepant in specific patient populations with co-morbidities (’598 Patent, col. 1:41-45). The invention is a method for treating migraine in a patient with severe renal impairment or end-stage renal disease, comprising the administration of 10 mg of atogepant once daily (’598 Patent, Abstract; Claim 1).
Asserted Claims
The complaint does not specify asserted claims; independent claim 1 is representative.
Accused Features
The accused feature is Defendants' ANDA filing for a 10 mg generic atogepant tablet. If approved, the product's label would allegedly instruct its use for migraine prevention in patients, including those with severe renal impairment, thereby practicing the claimed method (Compl. ¶¶1, 157, 160).
III. The Accused Instrumentality
Product Identification
The accused instrumentalities are Defendants’ proposed generic atogepant oral tablets in 10 mg, 30 mg, and 60 mg dosage forms, for which Defendants submitted ANDA No. 221029 to the FDA for approval (Compl. ¶1).
Functionality and Market Context
The complaint alleges that Defendants' generic products are bioequivalent to Plaintiffs’ commercial product, QULIPTA® Tablets (Compl. ¶63). As such, they are intended to function as oral CGRP receptor antagonists for the preventive treatment of migraine in adults (Compl. ¶33). The complaint alleges that if approved, Defendants' generic products will have the same indication and safety information as QULIPTA® Tablets (Compl. ¶64). Defendants are alleged to be in the business of manufacturing and selling generic copies of branded pharmaceutical products and intend to launch their product before the expiration of the patents-in-suit (Compl. ¶¶10, 62).
No probative visual evidence provided in complaint.
IV. Analysis of Infringement Allegations
The complaint alleges infringement under 35 U.S.C. § 271(e)(2)(A), where the act of submitting an ANDA for a drug claimed in a patent constitutes an act of infringement to create federal court jurisdiction for the dispute (Compl. ¶73). The substantive infringement allegations are based on the premise that the proposed generic product, if commercially manufactured and sold, would infringe the asserted method claims, either directly or indirectly (Compl. ¶74). The following tables summarize the infringement theory for representative claims.
12,090,148 Patent Infringement Allegations
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| A method for the preventive treatment of migraine... comprising administering to the patient 60 mg atogepant... once daily for more than 12 weeks | Defendants' ANDA seeks approval to market a 60 mg tablet. Its proposed label will allegedly instruct physicians and patients to administer it once daily for the preventive treatment of migraine. | ¶¶1, 35, 64, 75 | col. 6:15-20 |
| wherein administration of atogepant is associated with a reduction in mean monthly migraine days | Defendants' product is alleged to be bioequivalent and therapeutically equivalent to QULIPTA®, and its label will reflect the same efficacy data, which includes a reduction in mean monthly migraine days. | ¶¶63, 64, 72 | col. 2:3-5 |
| and wherein administration of atogepant is associated with a reduction from baseline in body weight. | Defendants' proposed label must contain the same safety and efficacy information as the QULIPTA® label, which includes data showing an association with reduction in body weight. | ¶¶63, 64 | col. 47:5-17 |
12,350,259 Patent Infringement Allegations
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| A method for the preventive treatment of migraine in a patient undergoing concurrent treatment with a strong CYP3A4 inhibitor | Defendants' proposed label must match the QULIPTA® label, which includes specific instructions for administering atogepant to patients taking strong CYP3A4 inhibitors. | ¶¶35, 37, 64, 103 | col. 3:30-34 |
| the method comprising orally administering 10 mg atogepant once daily to the patient | Defendants' ANDA seeks approval for a 10 mg tablet, and its proposed label will allegedly instruct this specific dosing regimen for this patient sub-population. | ¶¶1, 35, 64 | col. 3:35-40 |
| wherein the patient's migraines are safely and effectively treated. | Defendants' product is alleged to be bioequivalent to QULIPTA®, and its label will demonstrate the same FDA-approved safety and efficacy profile. | ¶¶63, 64, 100 | col. 3:39-40 |
Identified Points of Contention
- Validity vs. Infringement: In Hatch-Waxman litigation, the primary dispute is typically over the validity and enforceability of the asserted patents, as asserted in Defendants' Paragraph IV certification (Compl. ¶57). Infringement analysis often centers on comparing the proposed generic label to the patent claims. The complaint does not yet have access to Defendants' ANDA or proposed label, stating that access has not yet been provided (Compl. ¶65).
- Scope Questions: A potential question for the court may be whether Defendants' proposed label will "carve out" the patented methods of use. For the ’259 Patent, this raises the question of whether a generic label could omit instructions for patients on strong CYP3A4 inhibitors, and if so, whether such a "skinny label" would avoid infringement.
- Technical Questions: A key factual question will be what is contained within Defendants' ANDA No. 221029. The sufficiency of Plaintiffs' infringement allegations may be evaluated in light of the details of Defendants' proposed product and its intended uses, once that information becomes available in discovery.
V. Key Claim Terms for Construction
The Term: "preventive treatment" (’148 Patent, Claim 1)
Context and Importance
This term defines the purpose of the claimed method. Its construction is central to distinguishing the invention from acute or abortive migraine treatments. Practitioners may focus on this term because the commercial product is approved for preventive use, and the scope of "preventive" could impact both infringement and validity analyses.
Intrinsic Evidence for Interpretation
- Evidence for a Broader Interpretation: The specification describes prophylactic treatment as reducing the "frequency and intensity of migraine attacks" (’148 Patent, col. 47:59-62), which could suggest any administration that achieves this goal, regardless of timing relative to an attack, qualifies.
- Evidence for a Narrower Interpretation: The patent's background explicitly distinguishes between "acute but not preventive treatment" and the invention's focus on filling a "treatment gap" for "oral migraine preventives" (’148 Patent, col. 1:43-48). This context suggests "preventive treatment" requires regular, scheduled administration to reduce the future likelihood of attacks, rather than treating an imminent or ongoing one.
The Term: "strong CYP3A4 inhibitor" (’259 Patent, Claim 1)
Context and Importance
The scope of this term defines the specific patient population to which the claimed method applies. A narrow or broad definition will directly affect the number of clinical scenarios that fall within the claim's scope.
Intrinsic Evidence for Interpretation
- Evidence for a Broader Interpretation: The patent does not provide an explicit definition based on a quantitative threshold of enzyme inhibition. A party could argue it encompasses any compound recognized by a person of ordinary skill in the art as having a strong inhibitory effect on the CYP3A4 enzyme.
- Evidence for a Narrower Interpretation: The specification provides specific examples of strong CYP3A4 inhibitors, namely "ketoconazole, itraconazole, or clarithromycin" (’259 Patent, col. 4:38-40). A party could argue that the term should be limited to these examples or to compounds with a pharmacologically equivalent level of inhibition, potentially as defined by regulatory bodies like the FDA.
VI. Other Allegations
Indirect Infringement
The complaint heavily relies on allegations of induced infringement. It alleges that Defendants know and intend that healthcare providers will prescribe, and patients will use, the proposed generic products according to the instructions in the proposed package insert. This act of following the label would allegedly constitute direct infringement of the method claims, which Defendants are alleged to have induced (Compl. ¶¶75-78, 103-106).
Willful Infringement
The complaint does not contain a formal count for willful infringement or a request for enhanced damages under 35 U.S.C. § 284. However, it alleges that Defendants had knowledge of the patents, at the latest, via the Notice Letter (Compl. ¶76, ¶104). The prayer for relief requests a declaration that this is an "exceptional case" for the purpose of awarding attorney fees under 35 U.S.C. § 285 (Compl. p. 30, ¶G).
VII. Analyst’s Conclusion: Key Questions for the Case
- A primary issue will be one of patent validity: will the asserted claims of the four patents-in-suit withstand Defendants' challenges of invalidity and/or unenforceability, as raised in their Paragraph IV certification? This is the central dispute in most Hatch-Waxman litigation.
- A second core issue will be one of infringement by labeling: does the language of Defendants’ proposed product label, as submitted in their ANDA, instruct or encourage physicians and patients to administer generic atogepant in a manner that meets all the limitations of the asserted method claims, thereby supporting a finding of induced infringement?
- A subsidiary question will relate to claim scope in specific populations: can the methods claimed for patients with co-morbidities (e.g., severe renal impairment in the ’598 patent) or those taking concomitant medications (e.g., strong CYP3A4 inhibitors in the ’259 patent) be successfully "carved out" of a generic label to design around infringement, and if so, have Defendants done so?